Abstract:Abstract Background Ovarian serous cystadenocarcinoma (OSC) is the most common pathological subtype of ovarian cancer (OC) associated with high mortality. Albeit dysregulated mitochondrial metabolism has been implicated with OC, the role of mitochondrial genes in OSC remains unclear. We sought to construct a model based on mitochondrial genes for prognosis prediction, drug guidance and immune feature analysis of OSC. Methods Differentially expressed genes (DEGs) and mitochondrial-related DEGs (MRGs) were identified through the Cancer Genome Atlas (TCGA)-OV dataset. Consensus clustering algorithm was applied to classify OSC patients into distinct MRGs subtypes. Prognosis-related MRGs were screened to construct the prognosis-related Risk score model, which was verified using GSE26193 dataset and immunohistochemistry (IHC) score model based on staining intensity and extent scores of MRGs. A visualized nomogram was developed to predict 1-, 3- and 5-year overall survival (OS) and drug response. The correlation of MRGs subtypes with risk subgroups and the association of Risk score model with immune response and infiltration were also investigated. Results 341 MRGs were identified from TCGA-OV, and OSC patients could be mainly divided into two MRGs subtypes. A novel prognostic Risk score model based on 7-MRGs, including ACOT13 , ACSS3 , COA6 , HINT2 , MRPL14 , NDUFC2 and NDUFV2 , was developed and validated via GSE26193 dataset and IHC score model. Patients in the low-risk group had a significantly longer OS. The nomogram exhibited good prognostic assessment accuracy in both training and validation datasets. Drug sensitivity analysis indicated that cisplatin, paclitaxel and docetaxel were more sensitive in the low-risk group; VEGFR inhibitor Axitinib, and BRAF inhibitors Vemurafenib and SB590885 showed better sensitivity in the high-risk group; moreover, patients in the low-risk group could have better anti-PD-1 immunotherapy response. Patients in “cluster1” MRGs subtype had lower risk scores and better immunotherapy response scores than the “cluster2” subgroup. More significant infiltrated tumor killing cells (CD8 + T cells) and higher M1 / M2 macrophage ratio were in “cluster1” patients. Conclusions Our novel 7 MRGs-based Risk score model has huge prospects to evaluate the prognosis and guide drug treatment. The favorable prognosis associated with the low-risk group is closely related to better immune response and more significant anti-tumor cellular infiltration.

An EMT-based Gene Signature Enhances the Clinical Understanding and Prognostic Prediction of Patients with Ovarian Cancers

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

Establishing a Prognostic Signature Based on Epithelial–Mesenchymal Transition-Related Genes for Endometrial Cancer Patients

Construction of a mitochondria genes-based model for prognosis prediction, drug guidance and immune feature analysis in ovarian serous cystadenocarcinoma

An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer

Identification of EMT-Related Gene Signatures to Predict the Prognosis of Patients With Endometrial Cancer

Systematic establishment and verification of an epithelial-mesenchymal transition gene signature for predicting prognosis of oral squamous cell carcinoma

Identification of an EMT‐related gene‐based prognostic signature in osteosarcoma

Establishing Molecular Subgroups of CD8+ T Cell-Associated Genes in the Ovarian Cancer Tumour Microenvironment and Predicting the Immunotherapy Response

Epithelial–Mesenchymal Transition-Based Gene Signature and Distinct Molecular Subtypes for Predicting Clinical Outcomes in Breast Cancer

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis Prediction in Ovarian Cancer.

Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq

EMT-related gene classifications predict the prognosis, immune infiltration, and therapeutic response of osteosarcoma

Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration

A Novel Epithelial-Mesenchymal Transition Molecular Signature Predicts The Oncological Outcomes In Colorectal Cancer

Metabolism-related gene vaccines and immune infiltration in ovarian cancer: A novel risk score model of machine learning

An EMT-related genes signature as a prognostic biomarker for patients with endometrial cancer

Establishment and validation of a novel invasion-related gene signature for predicting the prognosis of ovarian cancer

Identification and validation of a 9-gene signature for the prognosis of ovarian cancer by integrated bioinformatical analysis

Exosome-Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients

Tumor Immune Microenvironment Related Gene-Based Model to Predict Prognosis and Response to Compounds in Ovarian Cancer